Plasmapheresis for a Female with Cryptogenic New-Onset Refractory Status Epilepticus Not Benefiting from Monoclonal Antibody Therapy
Journal of the Korean Neurological Association
;
: 176-180, 2022.
Artigo
em Coreano
| WPRIM
| ID: wpr-926296
ABSTRACT
Monoclonal antibodies are pure antibodies that react to a specific epitope. Plasmapheresis is a treatment that separates and eliminates disease-causing substances before replacing the blood with plasma. Plasmapheresis has insufficient evidence for treating new-onset refractory status epilepticus (NORSE). Sequential plasmaphereses gradually improved a female cryptogenic NORSE patient who did not benefit from monoclonal antibody treatment.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Coreano
Revista:
Journal of the Korean Neurological Association
Ano de publicação:
2022
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS